Download App

Log in to access Online Inquiry
Company Overview More
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
CEO: Ingram Esq., Douglas S.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

SRPT Sarepta Therapeutics

74.650+3.750+5.29%
Close 05/27 20:00 ET
74.65000.00%
Post Mkt Price 05/27 16:01 ET
High
75.065
Open
71.030
Turnover
58.47M
Low
70.510
Pre Close
70.900
Volume
788.39K
Market Cap
6.53B
P/E(TTM)
Loss
52wk High
101.240
Shares
87.50M
P/E(Static)
Loss
52wk Low
61.280
Float Cap
6.21B
Bid/Ask %
81.82%
Historical High
181.830
Shs Float
83.20M
Volume Ratio
1.07
Historical Low
2.598
Dividend TTM
--
Div Yield TTM
700
P/B
7.62
Dividend LFY
--
Div Yield LFY
937.71%
Turnover Ratio
0.95%
Amplitude
6.42%
Avg Price
74.165
Lot Size
1
Float Cap
6.21B
Bid/Ask %
81.82%
Historical High
181.830
Shs Float
83.20M
Volume Ratio
1.07
Historical Low
2.598
Dividend TTM
--
P/B
7.62
Dividend LFY
--
Turnover Ratio
0.95%
Amplitude
6.42%
Avg Price
74.165
Lot Size
1
Price Forecast

No Data

News

Comment